• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Licensing Terms and Agreements in Pharma, Biotech and Diagnostics Product Image Special Offer Sale Banner

Licensing Terms and Agreements in Pharma, Biotech and Diagnostics

  • ID: 2889861
  • August 2014
  • Region: Global
  • 1195 pages
  • CurrentPartnering
Special Offer Banner
20%
OFF
Offer ends 31st Dec 2014

The Licensing Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the licensing deals and agreements entered into by the worlds leading life science companies.

The report provides a detailed understand and analysis of how and why companies enter licensing deals.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred – contract documents provide this insight where press releases and databases do not.

This report contains links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by biopharma companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant READ MORE >

Note: Product cover images may vary from those shown

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in licensing dealmaking

2.1. Introduction
2.2. Definition of licensing deals
2.3. Success factors for licensing deals
2.4. When licensing can be useful
2.5. Attributes of licensing deals
2.6. Trends in licensing deals since 2009
2.7. Option to license
2.8. Adding co-promotion to the mix
2.9. The future of licensing deals

Chapter 3 – Overview of licensing deal structure

3.1. Introduction
3.2. Pure versus multi-component licensing deals
3.3. Pure licensing agreement structure
3.3.1. Example licensing agreements
3.3.1.a. Case study 1: Ignyta – Nerviano Medical Sciences – November 2013
3.3.1.b. Case study 2: Sanofi - Pozen – September 2013
3.4. Licensing rights as part of a wider alliance agreement
3.4.1. Example licensing clauses
3.4.1.a. Case study 3: 4D Molecular Therapeutics – UniQure – January 2014
3.4.1.b. Case study 4: Kyowa Hakko Kirin – Ultragenyx Pharmaceuticals – September 2013
3.4.2. Example licensing option right clauses
3.4.2.a. Case study 5: Forest Laboratories - Trevena – May 2013
3.4.2.b. Case study 6: Abbvie – Receptos – March 2013

Chapter 4 – Leading licensing deals

4.1. Introduction
4.2. Top licensing deals by value
4.3. Most active licensing dealmakers
4.3.1 Most active licensing dealmakers by therapy
4.3.2. Most active licensing dealmaker by stage of development
4.4. Bigpharma licensing deal activity
4.4. Bigbiotech licensing deal activity

Chapter 5 – Licensing deal term benchmarks

5.1. Introduction
5.2.1. Licensing headline values
5.2.2. Licensing upfront payments
5.2.3. Licensing milestone payments
5.2.4. Licensing royalty rates

Chapter 6 – Bigpharma licensing deals

6.1. Introduction
6.2. How to use licensing deals
6.3. Company licensing agreement listings

Chapter 7 – Bigbiotech licensing deals

7.1. Introduction
7.2. How to use licensing deals
7.3. Company licensing agreement listings

Chapter 8 – Licensing contract directory 2009-2014

8.1. Introduction
8.2. Company A-Z

Appendices

Appendix 1 – Licensing dealmaking - by financial disclosure
Appendix 2 – Licensing dealmaking - by companies A-Z
Appendix 3 – Licensing dealmaking - by stage of development
Appendix 4 – Licensing dealmaking - by therapeutic target
Appendix 5 – Licensing dealmaking - by technology type
Table of figures
Figure 1: Definition of licensing
Figure 2: Situations where licensing can prove useful
Figure 3: Key attributes of a licensing deal
Figure 4: Trends in licensing deal announcements, 2009-2014
Figure 5: Licensing deals signed at each phase of development, 2009-2014
Figure 6: Licensing deals by therapy area, 2009-2014
Figure 7: Licensing agreements – what should a contract include?
Figure 8: Components of the licensing deal structure
Figure 9: Top licensing deals by value since 2009 exceeding $1bn
Figure 10: Most active licensing dealmakers 2009-2014
Figure 11: Most active licensing dealmakers 2009-2014 by therapy area
Figure 12: Most active licensing dealmakers 2009-2014 – by stage of development
Figure 13: Bigpharma – top 50 – licensing deals 2009 to 2014
Figure 14: Bigpharma licensing deal frequency - 2009 to 2014
Figure 15: Bigbiotech – top 50 – licensing deals 2009 to 2014
Figure 16: Bigbiotech licensing deal frequency - 2009 to 2014
Figure 17: Licensing deal headline value distribution, US$million – discovery stage
Figure 18: Licensing deal headline value distribution, US$million – preclinical stage
Figure 19: Licensing deal headline value distribution, US$million – phase I stage
Figure 20: Licensing deal headline value distribution, US$million – phase II stage
Figure 21: Licensing deal headline value distribution, US$million – phase III stage
Figure 22: Licensing deal headline value distribution, US$million – regulatory stage
Figure 23: Licensing deal headline value distribution, US$million – marketed stage
Figure 24: Summary median licensing headline value by stage of development, 2009-2014
Figure 25: Licensing deal upfront payment distribution, US$million – discovery stage
Figure 26: Licensing deal upfront payment distribution, US$million – preclinical stage
Figure 27: Licensing deal upfront payment distribution, US$million – phase I stage
Figure 28: Licensing deal upfront payment distribution, US$million – phase II stage
Figure 29: Licensing deal upfront payment distribution, US$million – phase III stage
Figure 30: Licensing deal upfront payment distribution, US$million – regulatory stage
Figure 31: Licensing deal upfront payment distribution, US$million – marketed stage
Figure 32: Summary median licensing upfront payments by stage of development, 2009-2014
Figure 33: Licensing deal milestone distribution, US$million – discovery stage
Figure 34: Licensing deal milestone distribution, US$million – preclinical stage
Figure 35: Licensing deal milestone distribution, US$million – phase I stage
Figure 36: Licensing deal milestone distribution, US$million – phase II stage
Figure 37: Licensing deal milestone distribution, US$million – phase III stage
Figure 38: Licensing deal milestone distribution, US$million – regulatory stage
Figure 39: Licensing deal milestone distribution, US$million – marketed stage
Figure 40: Licensing deals with royalty rates, %
Figure 41: Licensing deal royalty rate distribution, US$million – discovery stage
Figure 42: Licensing deal royalty rate distribution, US$million – preclinical stage
Figure 43: Licensing deal royalty rate distribution, US$million – phase I stage
Figure 44: Licensing deal royalty rate distribution, US$million – phase II stage
Figure 45: Licensing deal royalty rate distribution, US$million – phase III stage
Figure 46: Licensing deal royalty rate distribution, US$million – regulatory stage
Figure 47: Licensing deal royalty rate distribution, US$million – marketed stage
Figure 48: Summary median licensing royalty rate by stage of development, 2009-2014
Figure 49: Online partnering resources
Figure 50: Deal type definitions

Note: Product cover images may vary from those shown

Key findings:

- Over 4,500 licensing deals announced in the last five years alone
- Pharma and Biotech industries are the most active licensors
- Average licensing deal value- $38.7 million since 2009
- Most partnered technology areas: small molecules, drug delivery, diagnostics, biological compounds
- Discovery and preclinical are the popular stages of deal signing
- Oncology is the most partnered therapeutic area followed by infectious diseases

The vast majority of collaborative R&D deals also incorporate some type of licensing - either in the form of embedded licensing terms or an agreement to enter a licensing deal should certain milestone be achieved in the collaboration.

Note: Product cover images may vary from those shown

Johnson&Johnson
Novartis Roche Pfizer Sanofi Merck and Co GlaxoSmithKline Bayer Fresenius AstraZeneca Eli Lilly Abbott Boehringer Ingelheim Teva Abbvie Amgen Takeda Bristol-Myers Squibb Novo Nordisk Baxter Merck KGaA Otsuka Astellas Daiichi Sankyo Gilead Sciences Actavis Biogen Idec Mylan Celgene Allergan Eisai Servier Valeant Pharmaceuticals CSL Shire UCB
Chugai Mitsubishi Tanabe Hospira Dainippon Sumitomo Forest Menarini Kyowa Hakko Kirin Grifols Shionogi Lundbeck Aspen Pharmacare Endo Pharmaceuticals Sun Pharmaceuticals Purdue

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos